Connect Biopharma Holdings Ltd
CNTBNasdaqHealthcare · Pharmaceutical Preparations · E9 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $64,000 | $26.0M | $0 |
| Operating income | −$58.1M | −$22.5M | −$69.1M |
| Net income | −$55.5M | −$15.6M | −$62.1M |
| Total assets | $56.1M | $101.3M | $127.4M |
| Total liabilities | $14.1M | $9.1M | $25.9M |
| Equity | $42.0M | $92.2M | $101.5M |
| EPS (diluted) | $-1.00 | $-0.28 | $-1.13 |
| Shares out. | 55.3M | 55.3M | 55.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −90740.6%
- Net margin
- −86687.5%
- Return on equity
- −132.2%
- Return on assets
- −98.9%
- Return on capital (ROCE)
- −136.8%
- Liabilities / assets
- 25.1%
- Debt / equity
- 0.34×
- Book value / share
- $0.76
- Revenue growth (YoY)
- −99.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -22.77distress
- Accruals / assets
- −7.6%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Wei ZhengPassive (13G)May 15, 2026
- Biofortune IncPassive (13G)Apr 14, 2026
- Panacea Innovation LtdActivist (13D)Apr 1, 2026
- Ikarian Capital, LlcPassive (13G)Feb 17, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Xanthopoulos Kleanthis GabrielDirector | Mar 31, 2026 | Grant | 2,816 | $0.00 |
| Liu Jean IDirector | Mar 31, 2026 | Grant | 5,061 | $0.00 |
| Huang JamesDirector | Mar 31, 2026 | Buy | 1.2M | $3.45 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.2M | 8.3 | +2.1% |
| Apr 30, 2026 | 1.1M | 4.8 | +14.0% |
| Apr 15, 2026 | 994,618 | 2.0 | +65.4% |
| Mar 31, 2026 | 601,458 | 1.6 | +58.8% |
| Mar 13, 2026 | 378,698 | 2.6 | +24.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Regulation FD disclosure · Other material eventApr 23, 2026
- Results of operationsMar 31, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosure · Other material eventMar 30, 2026
- Director / officer changeDec 23, 2025
- Results of operationsNov 12, 2025
- Regulation FD disclosureSep 16, 2025
- Results of operationsAug 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- F-3May 15, 2026
- 10-QMay 12, 2026
- 8-KMay 12, 2026
- 8-KApr 23, 2026
- SCHEDULE 13GApr 14, 2026
- 4FORM 4Apr 2, 2026
- 4FORM 4Apr 2, 2026
- 4Apr 1, 2026
- SCHEDULE 13D/AApr 1, 2026
- 10-KMar 31, 2026
- 8-KMar 31, 2026
- 8-KMar 30, 2026
- 3Mar 18, 2026
- 3FORM 3Mar 16, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.